Exact Sciences moves up time to profitability to most recent quarter


Accelerating its anticipated time to profitability, cancer screening test maker Exact Sciences Corp. said Sunday it expects profitability for the fourth quarter of 2022 and for the full-year 2023.

Previous Biotech company Calithera plans its own death. Will others follow?
Next Absci announces AI breakthrough in designing therapeutic antibodies